Answers are grounded in this paper and cite their sources.
Sickle cell disease (SCD) is highly prevalent in Sub-Saharan Africa (SSA), yet the region bears the greatest burden of adverse pregnancy outcomes. This systematic review synthesises evidence on maternal and perinatal outcomes in pregnant women with SCD in SSA. Following PRISMA 2020 guidelines, we searched PubMed, Scopus, Web of Science, and WHO Global Index Medicus from inception to 31 December 2025. The SPIDER framework guided eligibility. Included studies were cross-sectional, cohort, case-control, or randomised controlled trials reporting quantitative maternal or perinatal outcomes in pregnant women with confirmed SCD. Narrative and systematic reviews, guidelines, and studies of sickle cell trait were excluded. Nine studies met the inclusion criteria, drawn from three countries (Nigeria, Ghana, and Côte d’Ivoire). Maternal mortality ranged from 0% to 7.5% across SSA studies; perinatal mortality from 2.7% to 16.1%. Vaso-occlusive crises (42.9%), anaemia (39.3–63.8%), and pregnancy-induced hypertension (32.1% in one study) were the most common maternal complications. Preterm birth (18.2–33.3%), low birth weight (30–38%), and stillbirth (10–20%) dominated perinatal outcomes. In one single-centre before–after study from Ghana, introduction of multidisciplinary care was associated with a fall in maternal case fatality from 9.5% to 1.1% over 13 months, and a rate of 2.8% over the following 43 months. In the only randomised trial (PIPSICKLE), low-dose aspirin (100 mg daily) showed no benefit for a composite of intrauterine growth restriction, perinatal death, or miscarriage, and was associated with more sickle cell crises (IRR 1.04, 95% CI 1.01–1.08) and more maternal deaths (10/239 vs. 2/237; RR 4.96, 95% CI 1.18–20.92), although the number of deaths was small and the confidence interval wide. SCD in pregnancy in SSA carries high rates of maternal and perinatal morbidity and mortality. Evidence that multidisciplinary care improves outcomes comes from a single uncontrolled before–after study and needs confirmation. Low-dose aspirin showed no benefit and was associated with harm in one randomised trial, which warrants caution pending further evidence. Large, prospective, multicentre trials and population-based registries are urgently needed to guide evidence-based care in high-prevalence settings.
No takes yet. Share an insight, caveat, or question.
Awosan et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: